Company Description
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.
It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.
It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction.
Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2016 |
| IPO Date | Jul 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 140 |
| CEO | Faraz Ali |
Contact Details
Address: 171 Oyster Point Boulevard, Suite 500 South San Francisco, California 94080 United States | |
| Phone | 650 825 6990 |
| Website | tenayatherapeutics.com |
Stock Details
| Ticker Symbol | TNYA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001858848 |
| CUSIP Number | 87990A106 |
| ISIN Number | US87990A1060 |
| Employer ID | 81-3789973 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Faraz Ali M.B.A. | Chief Executive Officer and Director |
| Dr. Deepak Srivastava M.D. | Scientific Founder, Chairman of Scientific Advisory Board and Director |
| Dr. Whittemore G. Tingley M.D., PH.D. | Chief Medical Officer |
| Dr. Eric N. Olson Ph.D. | Scientific Founder and Member of Scientific Advisory Board |
| Dr. Bruce R. Conklin | Scientific Founder |
| Dr. Saptarsi Haldar M.D. | Scientific Founder |
| Dr. Sheng Ding Ph.D. | Scientific Founder |
| Dr. Benoit G. Bruneau Ph.D. | Scientific Founder |
| Chihiro Saito | Senior Accounting and Financial Operations and Interim Principal Accounting Officer |
| Dr. Kee-Hong Kim Ph.D. | Chief Technology Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 17, 2024 | 8-K | Current Report |
| Dec 17, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | 8-K | Current Report |
| Sep 17, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Sep 16, 2024 | 8-K | Current Report |
| Aug 16, 2024 | 144 | Filing |
| Aug 16, 2024 | 144 | Filing |